5.2(top 5%)
impact factor
2.1K(top 10%)
papers
73.9K(top 5%)
citations
107(top 5%)
h-index
5.8(top 5%)
impact factor
2.9K
all documents
78.6K
doc citations
156(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Virus-like particles in vaccine developmentExpert Review of Vaccines2010671
2CpG DNA as a vaccine adjuvantExpert Review of Vaccines2011670
3Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implicationsExpert Review of Vaccines2015636
4Vaccines for fish in aquacultureExpert Review of Vaccines2005583
5The fundamental link between pneumococcal carriage and diseaseExpert Review of Vaccines2012519
6Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responsesExpert Review of Vaccines2010443
7Poultry coccidiosis: recent advancements in control measures and vaccine developmentExpert Review of Vaccines2006436
8GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectivesExpert Review of Vaccines2007432
9Adjuvant system AS01: helping to overcome the challenges of modern vaccinesExpert Review of Vaccines2017353
10Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsionExpert Review of Vaccines2012281
11Virus-like particles: flexible platforms for vaccine developmentExpert Review of Vaccines2007280
12Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant SystemsExpert Review of Vaccines2011280
13Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccinesExpert Review of Vaccines2002265
14Technologies for enhanced efficacy of DNA vaccinesExpert Review of Vaccines2012265
15The history of MF59®adjuvant: a phoenix that arose from the ashesExpert Review of Vaccines2013254
16MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infectionExpert Review of Vaccines2007245
17Vero cell platform in vaccine production: moving towards cell culture-based viral vaccinesExpert Review of Vaccines2009241
18Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practiceExpert Review of Vaccines2008234
19Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiationExpert Review of Vaccines2007233
20Nanoparticles and microparticles as vaccine-delivery systemsExpert Review of Vaccines2007232
21Molecular mechanisms for enhanced DNA vaccine immunogenicityExpert Review of Vaccines2016231
22Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529Expert Review of Vaccines2003222
23The use of Toll-like receptor 7/8 agonists as vaccine adjuvantsExpert Review of Vaccines2013214
24Microparticles as vaccine adjuvants and delivery systemsExpert Review of Vaccines2003205
25Yellow fever vaccineExpert Review of Vaccines2005202
26Repeated annual influenza vaccination and vaccine effectiveness: review of evidenceExpert Review of Vaccines2017201
27Chikungunya virus and prospects for a vaccineExpert Review of Vaccines2012197
28Epaxal®: a virosomal vaccine to prevent hepatitis A infectionExpert Review of Vaccines2008196
29The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protectionExpert Review of Vaccines2017194
30MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profileExpert Review of Vaccines2003192
31Trends in vaccine adjuvantsExpert Review of Vaccines2011186
32Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programsExpert Review of Vaccines2009185
33Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developmentsExpert Review of Vaccines2009184
34Vaccine adjuvant uses of poly-IC and derivativesExpert Review of Vaccines2015183
35Opportunities and challenges of developing thermostable vaccinesExpert Review of Vaccines2009181
36Impact of the Delta variant on vaccine efficacy and response strategiesExpert Review of Vaccines2021177
37Vaccination against foot-and-mouth disease virus: strategies and effectivenessExpert Review of Vaccines2009174
38New hepatitis B vaccine formulated with an improved adjuvant systemExpert Review of Vaccines2007171
39Effect of vaccine administration modality on immunogenicity and efficacyExpert Review of Vaccines2015171
40Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza controlExpert Review of Vaccines2017170
41The evolving history of influenza viruses and influenza vaccinesExpert Review of Vaccines2013168
42EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)Expert Review of Vaccines2016168
43Cationic liposomes as vaccine adjuvantsExpert Review of Vaccines2011166
44Preventing urinary tract infection: progress toward an effectiveEscherichia colivaccineExpert Review of Vaccines2012166
45SARS vaccines: where are we?Expert Review of Vaccines2009165
46Lipid-based mRNA vaccine delivery systemsExpert Review of Vaccines2015165
47Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonistsExpert Review of Vaccines2010164
48Restoring confidence in vaccines in the COVID-19 eraExpert Review of Vaccines2020160
49Chitosan-based systems for the delivery of vaccine antigensExpert Review of Vaccines2009158
50Natural and synthetic saponin adjuvant QS-21 for vaccines against cancerExpert Review of Vaccines2011158